An engineered E. coli strain sustains intratumoral nitric oxide production to boost effectiveness of tumor immunotherapy

An engineered E. coli strain sustains intratumoral nitric oxide production to boost effectiveness of tumor immunotherapy Fig. 1: ECN-NO alleviates tumor hypoxia and supports anti-PD-L1 therapy in a CD8+ T cell-dependent manner.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Xu, S. et al. Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03054-y (2026).


Source: Read Full Article

Sam Miller

Leave a Reply

Your email address will not be published. Required fields are marked *